Brii Biosciences Ltd. engages in advancing therapies for significant infectious diseases and other illnesses which have significant public health burdens. The firm also focuses on developing therapies for infectious diseases and central nervous system diseases. The company was founded by Zhi Hong on December 8, 2017, and is headquartered in Beijing, China.
Fundamental metrics to determine fair value of the stock
Company’s recent performance and margins
Dividend yield, history and sustainability
Financial position and solvency of the company